BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 15920040)

  • 1. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine.
    Davies M; Storms F; Shutler S; Bianchi-Biscay M; Gomis R;
    Diabetes Care; 2005 Jun; 28(6):1282-8. PubMed ID: 15920040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.
    Davies M; Lavalle-González F; Storms F; Gomis R;
    Diabetes Obes Metab; 2008 May; 10(5):387-99. PubMed ID: 18355327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
    Davies M; Evans R; Storms F; Gomis R; Khunti K
    Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
    Riddle MC; Rosenstock J; Gerich J;
    Diabetes Care; 2003 Nov; 26(11):3080-6. PubMed ID: 14578243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
    Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
    Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies.
    Davies M; Sinnassamy P; Storms F; Gomis R;
    Diabetes Res Clin Pract; 2008 Feb; 79(2):368-75. PubMed ID: 17980928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Titration of Insulin Glargine in Patients with Type 2 Diabetes Mellitus in Asia: Physician- Versus Patient-Led? Rationale of the Asian Treat to Target Lantus Study (ATLAS).
    ATLAS Study Group
    Diabetes Technol Ther; 2011 Jan; 13(1):67-72. PubMed ID: 21175274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of three algorithms for initiation and titration of insulin glargine in insulin-naive patients with type 2 diabetes mellitus.
    Dailey G; Aurand L; Stewart J; Ameer B; Zhou R
    J Diabetes; 2014 Mar; 6(2):176-83. PubMed ID: 23931125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does a patient-managed insulin intensification strategy with insulin glargine and insulin glulisine provide similar glycemic control as a physician-managed strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study: a randomized noninferiority trial.
    Harris SB; Yale JF; Berard L; Stewart J; Abbaszadeh B; Webster-Bogaert S; Gerstein HC
    Diabetes Care; 2014; 37(3):604-10. PubMed ID: 24170757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving metabolic control in sub-optimally controlled subjects with Type 1 diabetes: comparison of two treatment algorithms using insulin glargine.
    Gomis R; Storms F; Conget I; Sinnassamy P; Davies M;
    Diabetes Res Clin Pract; 2007 Jul; 77(1):84-91. PubMed ID: 17097185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial.
    Kennedy L; Herman WH; Strange P; Harris A;
    Diabetes Care; 2006 Jan; 29(1):1-8. PubMed ID: 16373887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
    Riddle M; Frias J; Zhang B; Maier H; Brown C; Lutz K; Kolterman O
    Diabetes Care; 2007 Nov; 30(11):2794-9. PubMed ID: 17698615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.
    Rosenstock J; Dailey G; Massi-Benedetti M; Fritsche A; Lin Z; Salzman A
    Diabetes Care; 2005 Apr; 28(4):950-5. PubMed ID: 15793205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TITRATION: A Randomized Study to Assess 2 Treatment Algorithms with New Insulin Glargine 300 units/mL.
    Yale JF; Berard L; Groleau M; Javadi P; Stewart J; Harris SB
    Can J Diabetes; 2017 Oct; 41(5):478-484. PubMed ID: 28803820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
    Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
    Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does a patient-administered titration algorithm of insulin glargine improve glycemic control?
    Edelman S
    Nat Clin Pract Endocrinol Metab; 2006 Feb; 2(2):78-9. PubMed ID: 16932261
    [No Abstract]   [Full Text] [Related]  

  • 19. More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naïve patients with type 2 diabetes mellitus.
    Polonsky W; Traylor L; Wei W; Shi R; Ameer B; Vlajnic A; Nicolucci A
    Diabetes Obes Metab; 2014 Mar; 16(3):255-61. PubMed ID: 24028669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes.
    Kudva YC; Basu A; Jenkins GD; Pons GM; Quandt LL; Gebel JA; Vogelsang DA; Smith SA; Rizza RA; Isley WL
    Diabetes Care; 2005 Jan; 28(1):10-4. PubMed ID: 15616226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.